• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, Rinvoq

by October 30, 2024
written by October 30, 2024

By Leroy Leo

(Reuters) -AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings, sending the drugmaker’s shares up 2% on Wednesday.

The company has been working to offset a decline in sales of Humira, once the world’s top-selling medicine, by pushing its newer immunology drugs Skyrizi and Rinvoq amid competition from multiple less-expensive biosimilars that hit the U.S. market last year.

While Humira’s sales volumes have increasingly shifted to other drugs over successive quarters this year, that has also benefited Skyrizi and Rinvoq, AbbVie (NYSE:ABBV)’s Chief Commercial Officer Jeffrey Stewart said on a post-earnings call on Wednesday.

Skyrizi recorded third-quarter sales of $3.21 billion, beating the average analyst estimate of $2.93 billion, according to data compiled by LSEG. Rinvoq reported sales of $1.61 billion, compared with expectations of $1.54 billion.

AbbVie’s core growth drivers in Skyrizi and Rinvoq are continuing to trend ahead of expectations, J.P.Morgan analyst Chris Schott (ETR:1SXP) said.

Arthritis drug Humira’s global sales of $2.23 billion in the third quarter missed estimates of $2.39 billion. Its U.S. sales fell 42%, partially due to the drug’s removal from pharmacy benefit managers’ lists of preferred drugs for reimbursement.

Pharmacy benefit managers, who act as middlemen with insurers, have instead been recommending biosimilars.

AbbVie now expects its full-year adjusted profit to be between $10.90 and $10.94 per share, compared with its prior forecast range of $10.67 to $10.87 per share.

On an adjusted basis, the company earned $3 per share in the third quarter, beating estimates by 9 cents.

The company also said it will increase its 2025 dividend by 5.8%, starting February.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
ECB does not need to stimulate economy, Schnabel says
next post
Exclusive-OpenAI builds first chip with Broadcom and TSMC, scales back foundry ambition

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Trump implies government could cut contracts and subsidies to Musk’s companies

      June 7, 2025
    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 5, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (505)
    • Stock (6,426)

    Latest News

    • Trump implies government could cut contracts and subsidies to Musk’s companies
    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring

    Popular News

    • Wall St indexes fall with inflation data and rates in focus
    • Stocks pause, currencies mixed on Trump tariff concerns

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy